Showing 2341-2350 of 5964 results for "".
- Score: Droplette Micro-infuser Named one of Time Magazine's Best Inventions of 2022https://practicaldermatology.com/news/score-droplette-micro-infuser-named-one-of-time-magazines-best-inventions-of-2022/2461427/Droplette’s Micro-Infuser Device is one
- Revance Shares Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessmenthttps://practicaldermatology.com/news/revance-shares-two-publications-in-the-aesthetic-surgery-journal-that-advance-glabellar-line-injection-technique-and-assessment/2461425/Two peer-reviewed articles in the Aesthetic Surgery Journal, the official journal of The Aesthetic Society, highlight the nuances of glabellar line injection technique and aim to improve patient outcomes, irrespective of the neuromodulator used. The
- ACR Study: Belimumab Improves CLE Toohttps://practicaldermatology.com/news/acr-study-belimumab-improves-cle/2461423/The B-cell inhibitor belimumab significantly improved cutaneous lupus erythematosus (CLE) whether or not patients also had systemic lupus erythematosus (SLE), according to research presented at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, Beli
- High Rates of Skin Conditions Seen Among Urban-living Indigenous Kids in High-Income Countrieshttps://practicaldermatology.com/news/high-rates-of-skin-conditions-seen-among-urban-living-indigenous-kids-in-high-income-countries/2461421/Many urban-living Indigenous children and young people in high-income countries are burdened with atopic dermatitis and bacterial skin infections, according to Aasystematic analysis in Pediatric Dermatology. Invest
- IFPA Launches All the Colors We Are to Call Attention to Diversity in Psoriatic Diseaseshttps://practicaldermatology.com/news/ifpa-launches-all-the-colors-we-are-to-call-attention-to-diversity-in-psoriatic-diseases/2461419/IFPA is launching a new image library that raises awareness of diversity in psoriatic disease. IFPA is the global organization representing all people with psoriatic disease,. Go to any image database, and type “psoriasis” in the search bar. The results? Invariably
- It's Time to Celebrate Allergan Aesthetics' Fourth Annual BOTOX Cosmetic Dayhttps://practicaldermatology.com/news/its-time-to-celebrate-allergan-aesthetics-fourth-annual-botox-cosmetic-day/2461413/Allergan Aesthetics is inviting people across the country to take a "Moment for You" on Wednesday, November 16 and celebrate the biggest event of the year for Botox Cosmetic. For this year's celebration, BOTOX® Cosmetic is sharing two exclusive offers availab
- One Year Data: Cutera’s AviClear Continues to Improve Acnehttps://practicaldermatology.com/news/one-year-data-cuteras-aviclear-comtinues-to-improves-acne/2461400/Cutera, Inc.’s AviClear improves acne in 92 percent of patients at one year, according to research presented at the Annual Fall Clinical Dermatology Conference in Las Vegas. Current clinical studies show that after three 30-minute treatment sessions, 90 percent of patients had a v
- Game Changer: Incyte’s Ruxolitinib Reverses Vitiligohttps://practicaldermatology.com/news/game-changer-incytes-ruxolitinib-reverses-vitiligo/2461392/Topical Ruxolitinib is highly effective for skin re-pigmentation in vitiligo, according to Phase III clinical trial results published in The New England Journal of Medicine. The study showed better than 75 percent improvement on face and 50 percent improvement on body fo
- Phase 3 Data: Opdivo Reduced Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/phase-3-data-opdivo-reduced-risk-of-recurrence-or-death-by-58-versus-placebo-in-patients-with-completely-resected-stage-iib-or-iic-melanoma/2461391/Bristol Myers Squibb shared results from the Phase 3 CheckMate -76K trial, in which Opdivo (nivolumab) as an adjuvant therapy demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo in patients with completely resected stage IIB
- Study: Psoriasis Does Not Appear to Increase Heart Attack Risk in People with Significant Kidney Diseasehttps://practicaldermatology.com/news/study-psoriasis-does-not-appear-to-increase-heart-attack-risk-in-people-with-significant-kidney-disease/2461387/Studies have suggested that psoriasis is an independent risk factor for heart attack in the general population, but investigators recently found that in people who also have end-stage renal disease, which shares many risk factors with heart disease, it is not. “There are a lot of